A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Moderna (MRNA) shares move higher after reporting ... sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen ...

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...

a key building block in mRNA manufacturing.” He continued: “OriCiro’s technology strategically complements our manufacturing expertise and further accelerates our research and development ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

If the current patent holders for mRNA shared their formula or waived their IP rights, which is currently being negotiated through the World Trade Organization (WTO), manufacturing and ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.